Endocrine Abstracts

Although differentiated thyroid cancer (DTC) has the third highest propensity to spread to the bone after breast and prostate cancer, there is a paucity of data concerning the treatment of bone metastasis (BM) in this setting. The MOSCATI (Metastasi OSsee da Carcinoma TIroideo) was a multicenter, retrospective study investigating the real-life outcome and management of BM in 143 patients (80 F, 63 M; median age 60 years) with DTC involving 10 specialized cente...

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...

Background: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease and the most frequent cause of hypercalcemia in outpatients with an estimated incidence of 20/100 000/year and prevalence in the general population of 0.1%–0.4%. Parathyroidectomy (PTX) is the only treatment that can achieve PHPT cure but a few medications can be used to control calcium levels, bone and kidney impairment.Aims: 1) To assess costs associated with...